{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0010742\nAge: 51\nGender: Female\nSample ID: P-0010742-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Colon Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 30.0%\n=============\nDNA Variants:\nAPC c.3927_3931del (p.E1309Dfs*4) - in 20.00% of 366 reads\nNRAS c.35G>A (p.G12D) - in 59.00% of 1328 reads\nPTPRD c.1311G>C (p.Q437H) - in 11.00% of 1097 reads\nRARA c.118G>A (p.A40T) - in 58.00% of 1182 reads\nTP53 c.626_627delGA (p.R209Kfs*6) - in 55.00% of 1040 reads\nCNA Data:\nFLT3 - High Level Amplification\nFLT1 - High Level Amplification\nCDK8 - High Level Amplification\nStructural Variants:\nPRMT8 - APC (TRANSLOCATION)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Colon Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin)\",\n    \"Prior Treatment or Resistance Status\": \"Standard first-line chemotherapy\",\n    \"Genomic Features\": {\n      \"APC mutation\": \"c.3927_3931del (p.E1309Dfs*4)\",\n      \"KRAS mutation\": \"c.35G>A (p.G12D)\",\n      \"TP53 mutation\": \"c.626_627delGA (p.R209Kfs*6)\",\n      \"PTPRD mutation\": \"c.1311G>C (p.Q437H)\",\n      \"RARA mutation\": \"c.118G>A (p.A40T)\",\n      \"CNA\": {\n        \"FLT3\": \"High Level Amplification\",\n        \"FLT1\": \"High Level Amplification\",\n        \"CDK8\": \"High Level Amplification\"\n      },\n      \"Structural Variant\": \"APC translocation involving PRMT8\"\n    },\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Colon Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Cetuximab or Panitumumab\",\n    \"Prior Treatment or Resistance Status\": \"Consider if RAS wild-type; RAS G12D mutation indicates resistance\",\n    \"Genomic Features\": {\n      \"KRAS mutation\": \"c.35G>A (p.G12D)\"\n    },\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs\"\n  },\n  \"Treatment 3\": {\n    \"Disease Name\": \"Colon Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Regorafenib\",\n    \"Prior Treatment or Resistance Status\": \"For refractory metastatic CRC\",\n    \"Genomic Features\": {\n      \"Amplifications\": [\"FLT3\", \"FLT1\", \"CDK8\"]\n    },\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs\"\n  }\n}"
}